References

(1) Abbate R, Gori A, Farsi A, et al. Monitoring of low molecular weight heparins in cardiovascular disease. Am J Cardiol 1998; 82:33L-36L.

(2) Anand S, Wells P, Hunt D, et al. Does this patient have deep vein thrombosis? JAMA 1998; 279:1094-1099

(3) Fareed J, Jeske W, Hoppensteadt D, et al. Low molecular weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 1998; 82:3L-10L.

(4) Gould M, Dembitzer A, Doyle R, et al.; Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Int Med 1999; 130:800-809.

(5) Hirsh J, Warkentin T, Raschke R, et al.; Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114:489S-510S.

(6) Kleinschmidt K, Charles R. The pharmacology of low molecular weight heparins. Emerg Med Clinics N America 2001; 19:1025-1051.

(7) Laposata M, Green D, Van Cott E, et al.; The clinical use and laboratory monitoring of low molecular weight heparin, danaparoid, hirudin, and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122:799-807.

(8) Merli G, Vanscoy G, Rihn T, et al.; Applying scientific criteria to therapeutic interchange: a balanced analysis of low molecular weight heparins. J Thrombosis and Thrombolysis 2001; 11:247-259.

(9) Van Ryn-McKenna J, Cai L, Ofosu F, et al.; Neutralization of enoxaparin induced bleeding by protamine sulfate. Thrombosis and Haemostasis 1990; 63:271-274.

(10) Warkentin T, Levine M, Hirsh J, et al.; Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. NEJM 1995; 332:1330-1335.

(11) Yusen R, Haraden B, Gage B, et al.. Criteria for outpatient management of proximal lower extremity deep venous thrombosis. Chest 1999; 115:972-979

Go Back To MDchoice.com